Drug Profile
Research programme: stem cell therapies - Gemstone Biotherapeutics
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Gemstone Biotherapeutics
- Class Stem cell therapies
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Vascular-disorders in USA (Parenteral)